(LOCM) Low-osmolar contrast media have a wide range of indications due to their lower side effects. The type of contrast media is an important risk factor for an adverse reaction.
LOCM have not completely replaced contrast media with higher osmolality due to their higher cost. Guidelines of professional organizations give recommendations for the selective use of low-osmolar contrast media for certain high-risk patients.
There are ionic and nonionic iodinated contrast materials with low osmolality available:
An adverse reaction occurs in low-risk patients who receive conventional ionic contrast agents more often than in high-risk patients who receive nonionic LOCM.

See also Contrast Enhancement, Biliary Contrast Agents, Safety of Contrast Agents and Contrast-Induced Nephropathy.

(CA) Contrast agents are used to change the imaging characteristics, resulting in additional information about anatomy, morphology or physiology of the human body. Radiocontrast agents (also called photon-based imaging agents) are used to improve the visibility of internal body structures in x-ray and CT procedures. Contrast agents are also used to increase the contrast between different tissues in MRI (magnetic resonance imaging) and ultrasound imaging. The ideal imaging agent provides enhanced contrast with little biological interaction.
First investigations with radiopaque materials are done shortly after the discovery of x-rays. These positive contrast agents attenuate x-rays more than body soft tissues due to their high atomic weight. Iodine and barium have been identified as suitable materials with high radiodensity and are used until today in x-ray and CT contrast agents. Iodine-based contrast agents are water-soluble and the solutions are used nearly anywhere in the body. Iodinated contrast materials are most administered intravenous, but can also be introduced intraarterial, intrathecal, oral, rectal, intravesical, or installed in body cavities. Barium sulfate is only used for opacification of the gastrointestinal tract. Negative contrast agents attenuate x-rays less than body soft tissues, for example gas.

Iodinated contrast media are differentiated in;

Intravascular iodinated contrast agents are required for a large number of x-ray and CT studies to enhance vessels and organs dependent on the blood supply. Injectable contrast agents are diluted in the bloodstream and rapidly distributed throughout the extracellular fluid. The main route of excretion is through the kidneys, related to the poor binding of the agent to serum albumin. The liver (gall bladder) and small intestine provide alternate routes of elimination particularly in patients with severe renal impairment. The use of special biliary contrast agents is suitable for gallbladder CT and cholecystograms because they are concentrated by the liver to be detectable in the hepatic bile.
The introduction of fast multi-detector row CT technology, has led to the development of optimized contrast injection techniques. The amount of contrast enhancement depends on the contrast agent characteristics, such as iodine concentration, osmolality, viscosity, and the injection protocol, such as iodine flux and iodine dose. Adverse reactions are rare and have decreased with the introduction of nonionic contrast agents.
See also Contrast Enhanced Computed Tomography, Abdomen CT, Contrast Media Injector, Single-Head CT Power Injector, Multi-Head Contrast Media Injector, Syringeless CT Power Injector, CT Power Injector.

Radiographic contrast media (RCM) contributes important information to the diagnostic process. Actual contrast agents are safe drugs. Adverse reactions are rare, the incidence and severity of side effects decrease with the use of nonionic and low-osmolar contrast media. Adverse reactions are diverse, ranging from mild physiological disturbances to very rare life-threatening anaphylactic or anaphylactoid reactions. Users of contrast agents must be aware of the risk factors and be prepared to promptly manage adverse effects.
Side effects that may occur with intravascular administration of contrast agents are also possible after administration by other paths. Increased risk to an adverse reaction includes patients with a history of a previous reaction to a contrast medium, a known sensitivity to iodine, or a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies).

See also Contrast-Induced Nephropathy, Iodide-Induced Hyperthyroidism and Idiosyncratic Reactions.

Ultravist® is an iodinated contrast agent with low osmolality and low viscosity, enabling ease of administration and rapid iodine delivery rate. Ultravist® is available in 4 concentrations. Introduced in Europe 1985 and in the US in 1995, Ultravist® is being used today in over 100 countries worldwide.
See also Low-Osmolar Contrast Media.

Osmolality is the number of moles of osmotically active particles (molecules) present in solution per kilogram of water.
High osmolality of contrast agents is related to some of the adverse reactions.

Osmolality of iodinated contrast media: